Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.46 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9281838 | 0.83 | APP (0.51) | ALDH1A1APPKDM4EMEN1KMT2A | |
| SCHEMBL16404492 | 0.79 | HPGD (0.55) | ALDH1A1APPKDM4EMEN1KMT2A | |
| SCHEMBL9227908 | 0.76 | KMT2A (0.59) | ALDH1A1APPMEN1KMT2AGAA | |
| SCHEMBL7699644 | 0.75 | ALDH1A1 (0.56) | ERN1ALDH1A1AGPAT2KDM4EMEN1 | |
| SCHEMBL5099550 | 0.75 | PDE4D (0.56) | ERN1ALDH1A1AGPAT2PTGES2PDE4D | |
| SCHEMBL10093048 | 0.75 | AGPAT2 (0.57) | ERN1ALDH1A1AGPAT2KDM4EMEN1 | |
| SCHEMBL2002844 | 0.74 | ERN1 (0.47) | ERN1ALDH1A1AGPAT2PTGES2PDE4D | |
| SCHEMBL2785782 | 0.73 | ALDH1A1 (0.53) | ERN1ALDH1A1AGPAT2ABL1KDM4E | |
| SCHEMBL17268971 | 0.73 | ERN1 (0.51) | ERN1ALDH1A1AGPAT2ABL1PTGES2 | |
| SCHEMBL29634149 | 0.73 | PTGDR2 (0.57) | ERN1ALDH1A1AGPAT2PTGES2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | ERN1 1147/4885ALDH1A1 1050/4885PRKCQ 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.